Shots:
- BMS reported topline data from P-II (TRANSCEND FL) trial assessing Breyanzi in pts with r/r indolent B-cell non-Hodgkin lymphoma incl. follicular lymphoma & marginal zone lymphoma (MZL)
- Study met its 1EP of significant ORR in the MZL cohort as well as its 2EP of CRR with durable responses & favorable safety
- Breyanzi (CD19-directed) is a genetically modified autologous T cell immunotherapy that contains 4-1BB costimulatory domain to enhance expansion & persistence of CAR T cells
Ref: BMS | Image: BMS
Related News:- BMS’ Opdivo Qvantig SC Injection Secures the US FDA’s Approval for Solid Tumor Opdivo Indications
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
